Anti-coagulant therapy with dabigatran for cystic fibrosis patients

Area of Science:

• Pulmonology
• Hematology
• Pharmacology

Background:

• Patients with cystic fibrosis (CF) have an elevated risk of venous thromboembolism (VTE), often linked to central venous catheter use.
• Traditional anticoagulants like coumarins and low molecular weight heparin present administration challenges in CF patients.

Observation:

• This case series reports the successful long-term anticoagulation therapy using dabigatran in two CF patients.
• Dabigatran, an oral direct thrombin inhibitor, was used as an alternative anticoagulant medication.

Findings:

• Dabigatran was successfully administered for long-term anticoagulation in CF patients.
• The study demonstrates the feasibility of using dabigatran in this specific patient population.

Implications:

• Dabigatran represents a potential alternative oral anticoagulant for managing VTE in cystic fibrosis patients.
• Further research is warranted to confirm the safety and efficacy of dabigatran in a larger CF cohort.